Jeremy J P Shaw
Overview
Explore the profile of Jeremy J P Shaw including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
72
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rodriguez D, Tummers B, Shaw J, Quarato G, Weinlich R, Cripps J, et al.
Cell Rep
. 2024 Jun;
43(6):114335.
PMID: 38850531
Perturbation of the apoptosis and necroptosis pathways critically influences embryogenesis. Receptor-associated protein kinase-1 (RIPK1) interacts with Fas-associated via death domain (FADD)-caspase-8-cellular Flice-like inhibitory protein long (cFLIP) to regulate both extrinsic...
2.
Paudel B, Tan S, Fox T, Ung J, Golla U, Shaw J, et al.
Blood Adv
. 2024 Jan;
8(5):1137-1142.
PMID: 38170742
No abstract available.
3.
Ung J, Tan S, Fox T, Shaw J, Taori M, Horton B, et al.
Cancers (Basel)
. 2023 Dec;
15(24.
PMID: 38136410
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy requiring urgent treatment advancements. Ceramide is a cell-death-promoting signaling lipid that plays a central role in therapy-induced cell death. We previously...
4.
Kalkavan H, Ruhl S, Shaw J, Green D
Nat Cancer
. 2023 Jun;
4(6):795-806.
PMID: 37277528
Regulated cell death (RCD) is essential for successful systemic cancer therapy. Yet, the engagement of RCD pathways does not inevitably result in cell death. Instead, RCD pathways can take part...
5.
Fisher-Wellman K, Kassai M, Hagen J, Neufer P, Kester M, Loughran Jr T, et al.
Cancers (Basel)
. 2023 Mar;
15(6).
PMID: 36980769
Acute myelogenous leukemia (AML), the most prevalent acute and aggressive leukemia diagnosed in adults, often recurs as a difficult-to-treat, chemotherapy-resistant disease. Because chemotherapy resistance is a major obstacle to successful...
6.
Rodriguez D, Quarato G, Liedmann S, Tummers B, Zhang T, Guy C, et al.
Proc Natl Acad Sci U S A
. 2022 Oct;
119(41):e2207240119.
PMID: 36191211
The absence of Caspase-8 or its adapter, Fas-associated death domain (FADD), results in activation of receptor interacting protein kinase-3 (RIPK3)- and mixed-lineage kinase-like (MLKL)-dependent necroptosis in vivo. Here, we show...
7.
Khokhlatchev A, Sharma A, Deering T, Shaw J, Costa-Pinheiro P, Golla U, et al.
FASEB J
. 2022 Sep;
36(10):e22514.
PMID: 36106439
Despite several new therapeutic options for acute myeloid leukemia (AML), disease relapse remains a significant challenge. We have previously demonstrated that augmenting ceramides can counter various drug-resistance mechanisms, leading to...
8.
Ung J, Tan S, Fox T, Shaw J, Vass L, Costa-Pinheiro P, et al.
Blood Rev
. 2022 Apr;
55:100950.
PMID: 35487785
Acute myeloid leukemia (AML) is an aggressive, heterogenous malignancy characterized by clonal expansion of bone marrow-derived myeloid progenitor cells. While our current understanding of the molecular and genomic landscape of...
9.
Lehman C, Spencer A, Hall S, Shaw J, Wulfkuhle J, Petricoin E, et al.
Sci Rep
. 2021 May;
11(1):10826.
PMID: 34031486
Head and neck cancer is the sixth most common cancer worldwide with a 5-year survival of only 65%. Targeting compensatory signaling pathways may improve therapeutic responses and combat resistance. Utilizing...
10.
Shaw J, Boyer T, Venner E, Beck P, Slamowitz T, Caste T, et al.
Mol Cancer Ther
. 2020 Oct;
19(12):2621-2633.
PMID: 33087509
Therapies for head and neck squamous cell carcinoma (HNSCC) are, at best, moderately effective, underscoring the need for new therapeutic strategies. Ceramide treatment leads to cell death as a consequence...